Clinical Data Novo Nordisk data shows oral semaglutide delivers significant weight loss in phase 3 trial PharmaTimesResponders achieved weight loss and improvements in physical functionMetabolic & GLP-1Read full story pharminent May 13, 2026 (Last updated: May 21, 2026) PharmaTimes Responders achieved weight loss and improvements in physical function Metabolic & GLP-1 Read full story Post navigation Previous: UAE approves AstraZeneca’s Baxfendy for hypertensionNext: Clock starts ticking on UK’s single patient record plan Related Stories Clinical Data Novo Nordisk starts trialing lower maintenance doses of oral Wegovy pharminent August 21, 2026 Clinical Data Cancer vaccine win restores Wall Street’s faith in Moderna pharminent August 20, 2026 Clinical Data New Taiho, Cullian data heats up lung cancer drug battle pharminent August 13, 2026
